LumakrasActive Ingredient(s): Sotorasib
FDA Approved: * May 28, 2021
Pharm Company: * AMGEN INC
Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer (NSCLC). It targets a specific mutation, G12C, in the protein KRAS which is responsible for various forms of cancer. The most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough. Sotorasib is an inhibitor... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.